Rosemont Pharmaceuticals to Buy Aytu BioPharma for $2.70 a Share
Rosemont Pharmaceuticals plans a $2.70-per-share cash tender offer for Aytu BioPharma. Here are the premium, the conditions and the expected closing date.

Rosemont Pharmaceuticals Holdings has agreed to acquire Aytu BioPharma (Nasdaq: AYTU) for $2.70 per share in cash, the companies announced Nov. 16. The deal will run as a tender offer, and Aytu said it expects to close in late December 2026.
The price is a 41.1% premium to Aytu’s 30-day volume-weighted average share price and a 51.7% premium to its closing price on Nov. 13, according to the announcement. Aytu’s board approved the transaction unanimously.
How the tender offer is structured
A wholly owned Rosemont subsidiary will launch an offer to buy all outstanding Aytu common stock. A second-step merger follows. Shares not tendered will be acquired in that merger at the same price, except for shares whose holders properly exercise appraisal rights.
The offer carries conditions. Holders of at least a majority of Aytu’s outstanding shares must tender, and certain outstanding warrants must be exercised or terminated.
Executive officers, directors and certain stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management have signed tender and support agreements. They agreed to tender their shares and to terminate or exercise any warrants they hold before the merger takes effect.
Why it matters for Aytu shareholders
Holders get a cash price instead of stock, and the premium is set against two reference points: the 30-day average and the Nov. 13 close. The offer has not started yet. The announcement says a solicitation to buy shares will only be made through tender offer documents filed with the Securities and Exchange Commission.
Shareholders who want to understand the mechanics can read our explainer on how a tender offer works for ordinary shareholders. The documents Rosemont and Aytu file will give the full terms and describe the process Aytu ran before agreeing to the sale.
Who the companies are
Aytu is a Denver-based pharmaceutical company focused on medicines for complex central nervous system diseases. Its prescription products include EXXUA (gepirone) extended-release tablets for major depressive disorder, plus treatments for attention-deficit/hyperactivity disorder.
Rosemont, headquartered in Leeds in the United Kingdom, develops, manufactures and supplies oral liquid medicines, aimed at patients who have difficulty swallowing solid tablets. The company says it has done this for nearly 60 years.
Aytu CEO Josh Disbrow said the agreement reflects the company’s work building its CNS and pediatric portfolio. Rosemont CEO Alok Sonig called the deal an important step in Rosemont’s US growth strategy.
What happens next
- Rosemont intends to start the tender offer and file a Schedule TO within 10 business days.
- Aytu will file a Schedule 14D-9 at about the same time. Both filings will carry further detail on the deal.
- Closing is anticipated in late December 2026, once the conditions to the tender offer are satisfied or waived.
Canaccord Genuity is financial advisor and Dorsey & Whitney LLP is legal counsel to Aytu. Bourne Partners is financial advisor and Ropes & Gray LLP is legal counsel to Rosemont. Sodali & Co is the information agent for the offer.
Sources: FinanzNachrichten.de, Yahoo Finance



